Geneos Wealth Management Inc. Prothena Corp Public LTD CO Transaction History

Geneos Wealth Management Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 08, 2021	BUY	$21.63 - $57.65 $562 - $1,498	26 New	26 $1,000
Q3 2018 Sep 07, 2021	SELL	$12.7 - $15.79 $1,003 - $1,247	-79 Closed	0 $0
Q2 2018 Sep 07, 2021	SELL	$10.99 - $44.21 $43 - $176	-4 Reduced 4.82%	79 $1,000
Q4 2017 Sep 07, 2021	BUY	$35.44 - $63.76 $70 - $127	2 Added 2.47%	83 $3,000
Q3 2017 Sep 07, 2021	SELL	$53.83 - $67.75 $1,937 - $2,439	-36 Reduced 30.77%	81 $5,000
Q4 2016 Sep 07, 2021	SELL	N/A	-28 Reduced 19.31%	117 $5,000
Q2 2016 Sep 07, 2021	SELL	N/A	-14 Reduced 8.81%	145 $5,000
Q1 2016 Sep 07, 2021	BUY	N/A	159	159 $6,000

186

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $646M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

Stay updated on Geneos Wealth Management Inc. with notifications on news.